Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF


Total Award Amount

  • 994220.00
  • Direct Costs

  • 790465.00
  • Sponsor Award Id

  • P01HL114470
  • Contributor

  • Gary Cutter   Investigator  
  • Joao De Andrade   Investigator  
  • Steven Duncan   Principal Investigator  
  • Tracy Luckhardt   Investigator